Exit
Register
Login
2026 MaTOS GU | Faculty PDF Access
Biomarkers of Response to PSMA Radioligand Therapy
Minimal Residual Disease (MRD): Tissue-agnostic or Tumor-informed?
NGS Molecular Testing in Blood vs Tissue or Other Biospecimens?
Liquid Biopsies in Genitourinary Cancers
Artificial Intelligence in Oncology
Biomarkers in Renal Cell Cancer
HIF2α Inhibitor Plus TKI
PDIGREE IPI/NIVO with VEGF TKI
Tivozanib in RCC
Radioligand Therapy in Prostate Cancer: Current Data & Future Directions
A Decade of Research Led to Reduced Toxicity with Novel CAR T-Cell Therapy in RCC
Gut Microbiome in Patients Treated with IO in RCC
Radiation Therapy for RCC
89Zr Girentuximab for PET/CT in ccRCC
Molecular Imaging in RCC
HIF2α Inhibitors in RCC
Non-Clear Cell RCC
Zanzalintinib and IO in RCC
IO-Associated Toxicity Management
Prostate Cancer Biomarkers
PARP inhibitors in mHSPC
Lutetium-177 PSMA in Prostate Cancer
AKT Inhibitors in Prostate Cancer
PROTAC AR Degraders
Pathology Classification of Bladder Cancer
(Neo)adjuvant ADC-based Therapies
Peri-Operative Therapies and Role of ctDNA
Therapy post EV/Pembro in Advanced Urothelial Cancer
Novel ADCs (Beyond anti-HER2/TROP2/Nectin4)
Therapies for Bladder Cancer Histology Subtypes/Variants
PSMA Targeted Treatment in Prostate Cancer: Lu-177 PSMA, Actinium-225 and Beyond
Bispecific T-Cell Engagers in Prostate Cancer
Neuroendocrine/Small Cell Prostate Cancer
Updates in Penile Cancer
Updates in Testicular Cancer
Finish Course
You need to enroll in this course to view this chapter
Lutetium-177 PSMA in Prostate Cancer
Enroll for $100,000.00
0% Course Complete